These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 22333173

  • 1. [The efficacy and safety of high-dose irbesartan in treatment of clinical proteinuria in patients with chronic kidney disease].
    Li X, Chen XD, Li ZX.
    Zhonghua Nei Ke Za Zhi; 2011 Dec; 50(12):1034-8. PubMed ID: 22333173
    [Abstract] [Full Text] [Related]

  • 2. Irbesartan effects on renal function in patients with renal impairment and hypertension: a drug-withdrawal study.
    De Rosa ML, de Cristofaro A, Rossi M, Baiano A, Cardace P, Albanese L, Vigorito C.
    J Cardiovasc Pharmacol; 2001 Sep; 38(3):482-9. PubMed ID: 11486253
    [Abstract] [Full Text] [Related]

  • 3. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ, Lewis JB.
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [Abstract] [Full Text] [Related]

  • 4. [IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting].
    Lehnert H, Bramlage P, Pittrow D, Kirch W.
    MMW Fortschr Med; 2003 Oct 09; 145 Suppl 3():81-7. PubMed ID: 15490772
    [Abstract] [Full Text] [Related]

  • 5. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.
    Bobrie G, I-ADD Study Investigators.
    Clin Ther; 2012 Aug 09; 34(8):1720-34.e3. PubMed ID: 22853847
    [Abstract] [Full Text] [Related]

  • 6. Effect of three months' treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31,793 patients.
    Strutz F, Bramlage P, Paar WD.
    Curr Med Res Opin; 2005 Sep 09; 21(9):1433-40. PubMed ID: 16197662
    [Abstract] [Full Text] [Related]

  • 7. Influence of irbesartan on the urinary excretion of cytokines in patients with chronic kidney disease.
    Ni J, Huang HQ, Lü LL, Zheng M, Liu BC.
    Chin Med J (Engl); 2012 Mar 09; 125(6):1147-52. PubMed ID: 22613545
    [Abstract] [Full Text] [Related]

  • 8. [Irbesartan in hypertensive non-diabetic advanced chronic kidney disease. Comparative study with ACEI].
    Coronel F, Cigarrán S, García-Mena M, Herrero JA, Calvo N, Pérez-Flores I.
    Nefrologia; 2008 Mar 09; 28(1):56-60. PubMed ID: 18336132
    [Abstract] [Full Text] [Related]

  • 9. Effect of felodipine with irbesartan or metoprolol on sexual function and oxidative stress in women with essential hypertension.
    Ma R, Yu J, Xu D, Yang L, Lin X, Zhao F, Bai F.
    J Hypertens; 2012 Jan 09; 30(1):210-6. PubMed ID: 22134388
    [Abstract] [Full Text] [Related]

  • 10. Randomized, double-blind comparison of irbesartan and enalapril for treatment of mild to moderate hypertension.
    Chiou KR, Chen CH, Ding PY, Chen YT, Ting CT, Huang JL, Chiang AH, Liu CP, Tseng CJ, Chao CT, Chang MS.
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 May 09; 63(5):368-76. PubMed ID: 10862446
    [Abstract] [Full Text] [Related]

  • 11. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.
    Rizos CV, Milionis HJ, Kostapanos MS, Florentin M, Kostara CE, Elisaf MS, Liberopoulos EN.
    Clin Ther; 2010 Mar 09; 32(3):492-505. PubMed ID: 20399986
    [Abstract] [Full Text] [Related]

  • 12. A comparison of the efficacy and safety of irbesartan/hydrochlorothiazide combination therapy with irbesartan monotherapy in the treatment of moderate or severe hypertension in diabetic and obese hypertensive patients: a post-hoc analysis review.
    Neutel JM.
    Postgrad Med; 2011 Jul 09; 123(4):126-34. PubMed ID: 21680997
    [Abstract] [Full Text] [Related]

  • 13. [The control rate of irbesartan/hydrochlorothiazide combination regimen in the treatment of Chinese patients with mild to moderate hypertension].
    Sun NL, Jing S, Chen J.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Jul 09; 33(7):618-21. PubMed ID: 16080809
    [Abstract] [Full Text] [Related]

  • 14. [Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals].
    Weisser B, Gerwe M, Braun M, Funken C.
    Arzneimittelforschung; 2005 Jul 09; 55(9):505-13. PubMed ID: 16229114
    [Abstract] [Full Text] [Related]

  • 15. Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood.
    Gartenmann AC, Fossali E, von Vigier RO, Simonetti GD, Schmidtko J, Edefonti A, Bianchetti MG.
    Kidney Int; 2003 Oct 09; 64(4):1450-4. PubMed ID: 12969165
    [Abstract] [Full Text] [Related]

  • 16. Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial.
    Lewin AJ, Weir MR.
    Clin Ther; 2008 Dec 09; 30(12):2354-65. PubMed ID: 19167594
    [Abstract] [Full Text] [Related]

  • 17. [Effect of irbesartan in proteinuric non-diabetic renal disease].
    de Gracia MC, Molina M, Navarro MJ, Garcia Hernández MA.
    Nefrologia; 2005 Dec 09; 25(5):509-14. PubMed ID: 16392300
    [Abstract] [Full Text] [Related]

  • 18. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study.
    Palatini P, Jung W, Shlyakhto E, Botha J, Bush C, Keefe DL.
    J Hum Hypertens; 2010 Feb 09; 24(2):93-103. PubMed ID: 19458624
    [Abstract] [Full Text] [Related]

  • 19. The efficacy and safety of irbesartan in primary hypertension even if a dose is missed: Results from the NO PROBLEM Study.
    Kabakci G, Kaya BE, Tulumen E, Kocabas U, Abali G, Deveci O, Aytemir K, Tokgozoglu L, Ozkutlu H.
    Blood Press Suppl; 2010 Feb 09; 1():5-9. PubMed ID: 19958075
    [Abstract] [Full Text] [Related]

  • 20. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
    Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group.
    N Engl J Med; 2001 Sep 20; 345(12):870-8. PubMed ID: 11565519
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.